Untargeted biomarker discovery aims to uncover previously unknown factors that associate with biologically relevant changes in human health and disease, such as those related to disease progression or treatment response. Most diseases, while singularly defined pathologically, actually represent diverse groupings of contributing factors and biological pathways. Identifying novel biomarkers can help to elucidate more of… Continue reading Data ≠ Insight: Improving Metabolomics Data Interpretation
Now On Demand | Hosted by AAPS Watch Now A key aspect of the drug discovery pipeline is evaluation of in vivo target engagement and subsequent biological response. While measures of target engagement are often optimized in cellular and preclinical systems, direct measures of tissue target engagement are often limited in human subjects as part of… Continue reading Identifying Non-Invasive Biomarkers of Target Engagement
Retrospective analyses conducted by major pharmaceutical companies on their drug pipelines have revealed that close to one-fifth of Phase II failures due to efficacy did not conclusively demonstrate adequate target exposure. This statistic emphasizes the importance of identifying target engagement biomarkers, which report on drug-target interactions and the cascade of biological changes that occur when a drug… Continue reading On the Mark? Identifying Biomarkers of Target Engagement
A drug candidate with an associated biomarker is 2−10x more likely to obtain FDA approval. Why? Because biomarkers help to stratify patient populations by elucidating the involvement of specific genes, proteins, and molecular alterations that give rise to their disease state. Therapies can then be aligned with patients most likely to benefit. The challenge is… Continue reading What is Discovery at Scale? Multiplying the Rate of Nontargeted Biomarker Profiling
Now On Demand | Hosted by AAPS Watch Now Diseases are singularly defined but often represent varied groupings of contributing factors and pathways that ultimately produce a shared pathology. Heterogeneous molecular pathogenesis creates heterogeneity in treatment responsiveness, which in turn drives up clinical trial size, timing, cost, and failure rates. For agents that ultimately achieve FDA… Continue reading Smaller, Faster & More Effective: Clinical Trial Enrichment Using Circulating Biomarkers
Learn about RExMap and our methods to advance biomarker-based discovery of microbially derived metabolites.
San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, the preeminent group of public-private partners focused on identifying, developing, and qualifying biomarkers to improve drug development and regulatory decision-making. Sapient’s Philip Worboys, PhD, Head of Translational Science,… Continue reading Sapient Joins the Foundation for the National Institutes of Health Biomarkers Consortium
High throughput technologies can now capture and measure a huge number of biological molecules within a single human cell or tissue, enabling clearer and more complete views of underlying biology and supporting development of molecularly targeted drug therapies. These molecules are found at the gene, protein, and metabolic level, giving rise to multiple ‘omics’ disciplines.… Continue reading Comparison of Omics Techniques and Biomarker Types
Immunotherapy has transformed the treatment of solid organ cancers, rapidly becoming a first line therapy with transformative durable response. While immunotherapies have favorable toxicity profiles compared to traditional chemotherapies, immunotherapy is associated with the development of immune-related adverse events (irAEs), an autoimmune condition incited by activation of the immune system. 20% to 60% of patients receiving… Continue reading Discovery of Biomarker to Predict Immunotherapy Related Autoimmunity
Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human metabolome at a rate is unmatched for discovery, uncovering previously unknown biomarkers that associate with early disease, disease progression, and drug response. By enabling sponsors rapidly identify, validate, and translate these novel biomarkers, we help accelerate their drug development programs, enrich clinical… Continue reading Untargeted Metabolomics Services for an Unprecedented Scale of Biomarker Discovery
